K
Kevin Bielamowicz Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
High Impact
Researcher
faculty
20 h-index
166 pubs
3,320 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Kevin Bielamowicz's research focuses on pediatric oncology and neuro-oncology, with a particular emphasis on developing and evaluating novel therapeutic strategies for brain tumors and other complex pediatric cancers. He has investigated CAR-T cell therapies targeting specific tumor antigens, such as HER2 and IL13Rα2, to mitigate tumor escape mechanisms. His work also includes evaluating the efficacy of targeted therapies, such as mirdametinib, in conditions like neurofibromatosis type 1-associated plexiform neurofibroma.
Bielamowicz has also contributed to understanding the outcomes of different radiotherapy techniques in pediatric medulloblastoma, comparing the incidence of endocrine deficiencies following proton and photon radiotherapy. His research extends to exploring combined immunotherapies for high-grade gliomas in the context of replication-repair deficiency syndromes and investigating the safety and efficacy of investigational agents in relapsed pediatric solid tumors, including medulloblastoma, neuroblastoma, and Ewing sarcoma.
His scholarly contributions are reflected in a h-index of 20 and over 3,200 citations across 166 publications. He is a designated high-impact researcher and leads a research group at the University of Arkansas for Medical Sciences. Key collaborators include Murat Gökden, Sateesh Jayappa, Kathleen Danielle Aldrich, and Gregory W. Albert, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 20
- Publications: 166
- Citations: 3,320
Selected Publications
-
Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance (2025)
-
Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma (2025)
-
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma (2024)
-
ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). (2024)
-
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures (2024)
-
Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse (2024)
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study (2024)
-
Isolated eyelid neonatal Langerhans cell histiocytosis (2024)
-
Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer (2023)
-
Early intervention palliative care in the pediatric population and its effects on quality of life (2023)
-
IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study (2022)
-
ETMR-15. Central Nervous System Embryonal Tumor with EWSR1 translocation: Evolving changes in histology, sequencing, and epigenetics at relapse in 2 patients and potential treatment implications (2022)
-
Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study (2021)
-
Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study (2021)
-
Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma (2021)
Grants & Funding
Collaboration Network
Top Collaborators
Kristen Fousek
Baylor College of Medicine (US)
19 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 19 shared publications
Daniel Landi
Duke University (US)
18 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 18 shared publications
Tiara T. Byrd
Baylor College of Medicine (US)
18 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 18 shared publications
Meenakshi Hegde
17 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 17 shared publications
Antonella Pignata
17 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 17 shared publications
Winfried S. Wels
17 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 17 shared publications
Nabil Ahmed
17 shared publications
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 17 shared publications
Vita S. Salsman
Baylor College of Medicine (US)
17 shared publications
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 17 shared publications
Christopher Szot
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
Heba Samaha
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
Steven Seaman
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
Lacey E. Dobrolecki
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
Htoo Zarni Oo
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
Nino Rainusso
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
John Hicks
16 shared publications
- Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
- Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Showing 5 of 16 shared publications
Similar Researchers
Based on overlapping research topics
Megan R. Reed
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Glioma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Lauren Appell
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Child and Adolescent Health
Cancer Treatment and Pharmacology
David K. Wilson
University of Arkansas for Medical Sciences
Child and Adolescent Health
Glioma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Lauren Elizabeth Appell
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Child and Adolescent Health
Cancer Treatment and Pharmacology
Murat Gökden
University of Arkansas for Medical Sciences
Glioma Diagnosis and Treatment
Neuroscience and Neural Engineering
Cancer-related molecular mechanisms research
Halyna Pokhylevych
University of Arkansas at Little Rock
Child and Adolescent Health
Glioma Diagnosis and Treatment
Cancer Treatment and Pharmacology